Great post, ImmunoATX.
Even with CRO oversight, the study director at Cellceutix will likely get bits and pieces of info, likely enough to get a feel for how things are going beyond the rate of enrollment. Of course, they may not and I certainly respect your view that Leo and Menon will not have a read on the trial until after each study site is closed out. You may be right.
Investigators at any clinical site where one or more patients doesn't suffer from severe oral mucositis during the 12 week trial will almost certainly wonder if it's a Brilacidin effect.
Updates on the Brilacidin Phase 2b ABSSSI study, which was also CRO administered, were appropriately limited to enrollment numbers. I expect the same for the B-OM trial.
Perhaps the best hint as to perceived efficacy during the course of the trial will be Leo in any way mentioning moving forward with Brilacidin for other GI inflammatory conditions. I'm not holding my breath.
Very patient and optimistic. And curious.
Market Data 
Markets 
AI
